Please login to the form below

Ono Pharmaceutical

This page shows the latest Ono Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Ono Pharmaceutical has distribution rights for Forxiga in Japan and will co-promote the drug for the treatment of CKD along with AstraZeneca.

Merck settles PD-1 patent lawsuit with BMS and Ono

The US drugmaker has agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625m to settle the patent infringement litigation - focusing on intellectual property in the area of PD-1 inhibitors - ... The initial payment and royalties will be shared
Merck decision to drop odanacatib lifts UCB/Amgen

Ono Pharmaceutical was also developing a drug in the class called ONO-5334 but pulled the programme in 2012 without giving reasons for the decision, while Medivir discontinued its MIV 701
Roche wins first approval for skin cancer drug Cotellic

That competition is only expected to get harder thanks to new PD1 inhibitors like Ono Pharmaceutical/BMS' Opdivo (nivolumab) and Merck &Co's Keytruda (pembrolizumab).
BMS signs Opdivo combination pact with Kyowa Hakko Kirin

Prior to this agreement, Kyowa Hakko Kirin, Bristol-Myers Squibb and Ono Pharmaceutical entered into a clinical trial collaboration agreement to study the combination of mogamulizumab and Opdivo in Japan. ... Ono is also a co-development partner with
FDA clears Amgen's Corlaner for heart failure

on ivabradine sales on the back of US approval and a roll-out in Japan, where the drug has been licensed to Ono Pharmaceutical.

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Deal Watch March 2017

Clearly on a roll with Japan, X-Chem has also signed a deal with Ono Pharmaceutical covering oncology targets. ... 190. Ambest Pharmaceutical. Sihuan Pharmaceutical. Acquisition. Manufacturing of injectables. 160. X-Chem.
Deal Watch July 2016

In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.
Pharma deals during July 2014

tremelimumab. Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments.
Pharma deals during August 2013

Onyx has sole marketing rights with the exception of Japan where it is licensed to Ono Pharmaceutical. ... the UK pharmaceutical market (11 per cent sales growth over the previous year) and will clearly strengthen Stada Arzneimittel's UK footprint.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

No results were found

Add my company

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Whitepaper: Closing the gap with compelling healthcare communications: Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers: Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs: It’s not a question of ‘if,’ it’s a question of ‘when.’...

Email:
Password: